While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs are already showing 160% revenue growth, positioning Eli Lilly for long-term success beyond the limited patent life of GLP-1 drugs.

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

Eli Lilly's new oral weight loss drug Foundayo is showing concerning early signs with flat prescription growth over five weeks post-launch, significantly trailing Novo Nordisk's oral Wegovy. However, analysts note that Foundayo's slower start may be temporary due to later pharmacy coverage and being a new drug formulation, while Lilly maintains a strong 60% U.S. market share and deep pipeline in the rapidly growing weight loss drug market.

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

The article recommends three high-yield dividend stocks for the second half of 2026: Novo Nordisk (3.5% yield) is positioned to regain market share in GLP-1 drugs with its superior pill formulation despite pricing pressures; Realty Income (5% yield) offers stable, conservative dividend growth through its diversified net lease REIT portfolio; and Enterprise Products Partners (5.9% yield) provides reliable energy infrastructure income through a toll-taker model insulated from oil price volatility.

Novo Nordisk trades near $50, down 75% from its June 2024 peak of $142.44, caught between a turnaround narrative and structural decline thesis. The stock has recovered from $35 lows on the back of a blockbuster oral Wegovy pill launch and Q1 earnings beat, but faces persistent headwinds from Eli Lilly's competitive dominance in GLP-1 drugs, pipeline setbacks with CagriSema, US pricing pressure, and patent erosion. At 11.8x forward earnings with a 3.6% dividend yield, the market is divided on whether the stock represents genuine value or a value trap.

Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

Eli Lilly's stock is predicted to reach $1,400 by end of 2026 (15% gain from July levels), driven by expanded drug access rather than efficacy. The company's new oral obesity drug Foundayo, combined with $27 billion in manufacturing expansion, direct pharmacy distribution, and Medicare pricing deals, positions it to reach patients that injectable competitors cannot. However, competition from Novo Nordisk, premium valuation, and execution risks remain concerns.

While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medicines.